For a patient with unipolar depression who is not treatment‑resistant but has irritability and mood lability, what is the recommended augmentation strategy and is lamotrigine appropriate as first‑line?

Augmentation with Bupropion or Buspirone is First-Line for Unipolar Depression with Irritability and Mood Lability

For a patient with unipolar depression (not treatment-resistant) presenting with irritability and mood lability, augment the current antidepressant with bupropion SR or buspirone rather than lamotrigine, as these agents have moderate-certainty evidence for efficacy in unipolar depression augmentation, while lamotrigine lacks proven benefit in unipolar disorders. 1

Why Not Lamotrigine First-Line?

The most recent comprehensive meta-analysis (2025) definitively shows that lamotrigine is not superior to placebo in unipolar depression, either as monotherapy or adjunct treatment 2. This finding held even after including three previously unpublished studies, strengthening the negative conclusion. While an earlier 2019 meta-analysis suggested possible benefit 3, the 2025 analysis with broader data supersedes this.

The Bipolar Spectrum Caveat

Critical pitfall to avoid: Irritability and mood lability may signal unrecognized subsyndromal bipolarity rather than pure unipolar depression 4. If your patient has:

• History of brief hypomanic periods (even subclinical)
• Family history of bipolar disorder
• Antidepressant-induced activation or mood switching
• Severe irritability disproportionate to depression severity

Then lamotrigine becomes appropriate as it demonstrates clear efficacy in bipolar depression (SMD: 0.155 for acute treatment; RR: 0.78 for prophylaxis) 2. In this scenario, avoid antidepressant monotherapy entirely and use lamotrigine or atypical antipsychotics (quetiapine, aripiprazole, cariprazine) as primary agents 4.

Recommended Augmentation Algorithm for True Unipolar Depression

First-Line Augmentation Options:

• Bupropion SR: Moderate-certainty evidence showing similar efficacy to switching strategies 1
• Buspirone: Moderate-certainty evidence for augmentation efficacy 1

Both agents have established evidence specifically in unipolar depression, unlike lamotrigine.

Second-Line Considerations:

• Lithium: Universally recommended across all 10 high-quality guidelines reviewed 5
• Atypical antipsychotics: Universally recommended, though specific agents vary by guideline 5

Evidence Limitations:

The 2023 American College of Physicians guideline highlights that only 2 small trials assessed augmentation with non-antidepressant medications 1, revealing a significant evidence gap. Most augmentation data comes from treatment-resistant populations, not first-episode partial responders with specific symptom profiles like irritability.

Why the Confusion About Lamotrigine?

Several factors create clinical confusion:

1. Geographic variation: The 2019 meta-analysis showed positive results when pooling six Chinese studies, but non-Chinese studies showed no statistical benefit 3

2. Bipolar vs. unipolar conflation: Lamotrigine's proven efficacy in bipolar depression 2 leads to inappropriate extrapolation to unipolar cases

3. Selective symptom effects: One small 2002 study suggested lamotrigine improved specific HAM-D items (depressed mood, guilt, work/interest) despite no overall score difference 6, but this hasn't been replicated in larger trials

4. Case reports: Recent dramatic case reports 7 describe rapid response, but these represent publication bias rather than typical outcomes

The evidence hierarchy is clear: guidelines and the most recent meta-analysis (2025) show no benefit for lamotrigine in unipolar depression 1, 2.